prod:prod_dcx-login
Customized Testing for Your Institution
No matter what your testing needs, we’ve got the right fit. If you’re a Laboratory Professional, Health Care Provider, or Health Care Executive, Cepheid’s menu of nearly 30 CE-IVD tests and platform flexibility means that faster answers are available in every setting. For Healthcare-Associated Infections, Critical Infectious Diseases, Virology, Sexual Health, or Oncology, Cepheid is the ideal diagnostic partner for improved clinical decision making and patient care.
Better Flexibility, Scalability & Consolidation.
Whenever You Need It.
Only Cepheid's GeneXpert® System can deliver game-changing flexibility with better answers. In 2006, Cepheid shifted the industry paradigm by taking the complexity out of the system and integrating it into an automated, easy to use, cartridge that delivers highly accurate PCR results.
Now, true platform consolidation and faster, more accurate results are a reality.
Video
On-Demand Testing with the Scalable GeneXpert® System: An Introduction
Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.
Video
On-Demand Testing with the Scalable GeneXpert® System: An Introduction
Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.
Webinar
Simplification of testing and treatment in the quest to eliminate hepatitis C infection
Globally, 71 million people are living with hepatitis C virus (HCV) infection, but the burden of HCV continues to increase. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <20% to 90% and the number of eligible persons receiving HCV treatment from <10% to 80%. To achieve these targets, targeted interventions are needed to enhance HCV testing, linkage to care, and treatment (“the HCV care cascade”). This presentation reviews available evidence on strategies that have been successfully used to enhance HCV testing, linkage to care.
More...
The Neglected STI: Trichomonas vaginalis
Among US women ages 14-49 the prevalence of Trichomonas vaginalis infection is estimated to be 2.3 million, though 85% of women found to have trichomoniasis report no symptoms. With varied complications such as increased risk of HSV-2/HIV acquisition, pelvic inflammatory disease and pre-term birth it has become increasingly important to identify and treat these patients quickly. This webinar will explore the renewed interest to screen and diagnose T. vaginalis in women. It will examine current testing methods available and provide updates regarding treatment options.
More...
Chlamydia and Gonorrhea testing in the ED and the Need for Evidence Based Medicine
In this webinar, Dr. Larissa May will discuss the diagnosis of sexually transmitted infections in the Emergency Department, the need for evidence-based medicine, and how same-visit treatment and management can be facilitated with on-demand testing for CT/NG.
More...
Key Links
Cepheid GeneXpert® Systems
Molecular Diagnostic Test Menu
Laboratory Professionals
